The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC

Although immune checkpoint and targeted therapies offer remarkable benefits for lung cancer treatment, some patients do not qualify for these regimens or do not exhibit consistent benefit. Provided that lung cancer appears to be driven by transforming growth factor beta signaling, we investigated th...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Oncol
Autors principals: Marwitz, Sebastian, Turkowski, Kati, Nitschkowski, Dörte, Weigert, Andreas, Brandenburg, Julius, Reiling, Norbert, Thomas, Michael, Reck, Martin, Drömann, Daniel, Seeger, Werner, Rabe, Klaus F., Savai, Rajkumar, Goldmann, Torsten
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6985561/
https://ncbi.nlm.nih.gov/pubmed/32039023
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.01550
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars